Authors


Sai Yendamuri, MD, FACS

Latest:

Investigators Seek to Resolve the “Obesity Paradox” in Lung Cancer

Smoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.


Federico Cappuzzo, MD

Latest:

Dr Cappuzzo on Findings from the RATIONALE-315 Trial in Resectable NSCLC

Federico Cappuzzo, MD, discusses findings from the phase 3 RATIONALE-315 trial in patients with resectable non–small cell lung cancer.



Andrew Spencer, MD, MBBS, FRACP, FRCPA

Latest:

Dr. Spencer on the Rationale to Evaluate Panobinostat in Multiple Myeloma

Andrew Spencer, MD, MBBS, FRACP, FRCPA, discusses the rationale to evaluate panobinostat in multiple myeloma.


Craig Kessler, MD

Latest:

Key Takeaways From Discussion

Physicians share key takeaways from the discussion on diagnosis and treatment of immune thrombocytopenia.



Yardlee Kauffman

Latest:

Integrating New Standards for Metastatic HER2+ Breast Cancer

The first-line standard of care for patients with HER2-postive metastatic breast cancer has long been held by the combination of pertuzumab, trastuzumab, and a taxane established with the publication of data from the CLEOPATRA trial.


Sherise Rogers, MD, MPH

Latest:

Dr Rogers on the NEO-Nal-IRI Trial in Pancreatic Adenocarcinoma

Sherise Rogers, MD, MPH, discusses the rationale for investigating irinotecan liposome injection plus 5-fluorouracil, leucovorin, and oxaliplatin in the preoperative treatment of patients with pancreatic adenocarcinoma.


Andrea Baccarelli, MD, PhD

Latest:

Dr. Baccarelli on the Effect of Environmental Factors on Cancer Diagnoses

Andrea Baccarelli, MD, PhD, discusses the effect of environmental factors on cancer diagnoses.


Dirk Schadendorf, MD, Essen University Hospital

Latest:

Dr. Schadendorf on Expected Toxicities With Encorafenib/Binimetinib/Pembrolizumab in BRAF V600E/K-Mutated Melanoma

Dirk Schadendorf, MD, discusses expected toxicities with the combination of encorafenib, binimetinib, and pembrolizumab in BRAF V600E/K-mutated melanoma.


Atrayee Basu-Mallick, MD

Latest:

Dr. Basu-Mallick on Established and Emerging Biomarker-Directed Therapies in CRC

Atrayee Basu-Mallick, MD, highlights established and emerging biomarker-directed therapies in colorectal cancer.


Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

Latest:

PI3K Inhibitors for PIK3CA-Mutated HR+ MBC

Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.


Chatrick Paul, SVP, Head of US Oncology Business, AstraZeneca

Latest:

Our Path Forward in Leading a Revolution in Cancer Care

Chatrick Paul of AstraZeneca shares his perspective on the mission to eradicate cancer as a leading cause of death


Gilberto Lopes, MD, University of Miami Health System

Latest:

Review of AENEAS Trial and Similar Agents

Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.


Sean Collins, MD, PhD

Latest:

Optimizing Care of Patients With Advanced Prostate Cancer: Conclusion

Summarizes the main points and benefits of multidisciplinary prostate cancer care.


Hackensack Meridian John Theurer Cancer Center

Latest:

Cancer Experts at Jersey Shore University Medical Center Implanting First Targeted Liver Tumor Treatment Pumps in Patients

Jersey Shore University Medical Center is among the first hospitals in New Jersey to provide the HAI pump, which is offered at few hospitals in the country, enabling the N.J. community to stay close to home for care.


Ezra Rosen, MD, PhD

Latest:

Dr Rosen on the Activity of Zotatifin Plus Abemaciclib/Fulvestrant in ER+ Breast Cancer

Ezra Rosen, MD, PhD, discusses the investigation of the triplet combination of zotatifin, abemaciclib, and fulvestrant in a phase 1/2 trial in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer.



Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center

Latest:

Optimizing the Selection of Novel Therapy for Patients With Advanced NSCLC

Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.


Amy Jones, MD

Latest:

Dr. Jones on Future Research Efforts in Pancreatic Cancer

Amy Jones, MD, discusses future research efforts in pancreatic cancer.


Giovanni Marconi, MD

Latest:

Dr Marconi on the Investigation of Tamibarotene Plus Azacitidine in Higher-risk MDS

Giovanni Marconi, MD, discusses ongoing research with the combination of tamibarotene and azacitidine in patients with higher-risk myelodysplastic syndrome.


Sam Klempner, MD

Latest:

Dr. Klempner on the Investigation of Adagrasib in KRAS G12C–Mutated mCRC

Sam Klempner, MD, discusses the investigation of adagrasib in KRAS G12C–mutated metastatic colorectal cancer.


Brian Henick, MD

Latest:

Dr Henick on the Use of Neoadjuvant Atezolizumab Plus Chemotherapy in NSCLC

Brian Henick, MD, discusses the 3-year updated data from a phase 2 trial investigating treatment with neoadjuvant atezolizumab plus chemotherapy in patients with resectable non–small cell lung cancer.


Benjamin Herzberg, MD

Latest:

Moving From Passive to Active Clinical Trials Enrollment

The Herbert Irving Comprehensive Cancer Center has developed processes to actively screen any patient with a relevant mutation for an open trial.


Nausheen Ahmed, MD

Latest:

Dr Ahmed on a Study of Real-World Outcomes With Brexu-Cel in Relapsed/Refractory MCL

Nausheen Ahmed, MD, discusses the rationale and design of a subgroup analysis of real-world outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma.



Kedar Kirtane, MD

Latest:

Dr Kirtane on the Design of the EVEREST-1 Trial Evaluating A2B530 in Solid Tumors

Kedar Kirtane, MD, discusses the design of the phase 1/2 EVEREST-1 trial, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with advanced solid tumors.


Shonali Midha, MD

Latest:

Dr Midha on Real-World Data With Teclistamab in Relapsed/Refractory Multiple Myeloma

Shonali Midha, MD, discusses real-world data with teclistamab in patients with relapsed/refractory multiple myeloma.


Faiz Anwer, MD

Latest:

Dr. Anwer on the Efficacy of CAR T-Cell Therapy in Multiple Myeloma

Faiz Anwer, MD, discusses the efficacy of CAR T-cell therapy in multiple myeloma.


Pannaga G. Malalur, MBBS

Latest:

Dr Malalur on Addressing Unmet Needs in Pancreatic Cancer

Pannaga G. Malalur, MBBS, discusses several unmet needs within pancreatic cancer, including the implementation of updated germline genetic testing guidelines, increased screening of high-risk patients, and improved sequencing of available therapeutics.